Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AZD7789 |
Synonyms | |
Therapy Description |
AZD7789 is a bispecific antibody that targets both programmed cell death protein 1 (PDCD1) and TIM3, potentially leading to altered antitumor response including enhanced T-cell mediated cell lysis, and inhibition of tumor growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD7789 | AZD 7789|AZD-7789 | PD-L1/PD-1 antibody 110 TIM-3 Antibody 8 | AZD7789 is a bispecific antibody that targets both programmed cell death protein 1 (PDCD1) and TIM3, potentially leading to altered antitumor response including enhanced T-cell mediated cell lysis, and inhibition of tumor growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05216835 | Phase Ib/II | AZD7789 | Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 1 |